// App-Quantinova.ai

3579 : Genetic variants of ATM and XRCC3 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.

Researchers

Presenter

  • Mitsukuni Suenaga

Principal Investigators

  • Shu Cao

  • Wu Zhang

  • Dongyun Yang

  • Martin D. Berger

  • Jordan David West

  • Yan Ning

  • Lisa Salvatore

  • Daniele Rossini

  • Carlotta Antoniotti

  • Ramu Inoue

  • Satoshi Matsusaka

  • Satoshi Okazaki

  • Yuji Miyamoto

  • Diana L. Hanna

  • Afsaneh Barzi

  • Fotios Loupakis

  • Heinz-Josef Lenz

Medical Centers

  • Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Los Angeles, CA

  • Department of Preventive Medicine, USC Norris Comprehensive Cancer Center, Los Angeles, CA

  • USC Norris Comprehensive Cancer Center, Los Angeles, CA

  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

  • Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy

  • San Filippo Neri Hospital, Rome, Italy

  • U.O. Oncologia Medica 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy

  • Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan

  • Department of Pharmacy,The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

  • Istituto Toscano Tumori, Pisa, Italy

  • University of Southern California, Los Angeles, CA

Locations

  • United States

  • Japan

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Breast cancer type 2 susceptibility protein

  • RAD51 Recombinase

  • Histone H2AX

  • X-Ray Repair Cross Complementing 3

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • Regorafenib

  • TAS102

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved